Cargando…
Substance GP-2250 as a New Therapeutic Agent for Malignant Peritoneal Mesothelioma—A 3-D In Vitro Study
Malignant peritoneal mesothelioma is a rare tumor entity. Although cytoreductive surgery and hyperthermic intraperitoneal chemotherapy have increased overall survival, its prognosis remains poor. Established chemotherapeutics include mitomycin C (MMC) and cisplatin (CP), both characterized by severe...
Autores principales: | Baron, Claudia, Buchholz, Marie, Majchrzak-Stiller, Britta, Peters, Ilka, Fein, Daniel, Müller, Thomas, Uhl, Waldemar, Höhn, Philipp, Strotmann, Johanna, Braumann, Chris |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267014/ https://www.ncbi.nlm.nih.gov/pubmed/35806313 http://dx.doi.org/10.3390/ijms23137293 |
Ejemplares similares
-
New Therapy Options for Neuroendocrine Carcinoma of the Pancreas—The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo
por: Buchholz, Marie, et al.
Publicado: (2022) -
The effect of GP-2250 on cultured virus-negative Merkel cell carcinoma cells: preliminary results
por: Gambichler, Thilo, et al.
Publicado: (2023) -
GP‐2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP‐Kinase and impairs the NF‐kB pathway in pancreatic cancer cells
por: Majchrzak‐Stiller, Britta, et al.
Publicado: (2023) -
In Vitro Experiments on the Effects of GP-2250 on BRAF-Mutated Melanoma Cell Lines and Benign Melanocytes
por: Gambichler, Thilo, et al.
Publicado: (2023) -
Innovative substance 2250 as a highly promising anti-neoplastic agent in malignant pancreatic carcinoma - in vitro and in vivo
por: Buchholz, M., et al.
Publicado: (2017)